
    
      Multicenter study aiming to collect patient's clinical data retrospectively and their
      histological samples prospectively.

      The cohort will include:

        -  30 patients PD-L1 > 50% treated with pembrolizumab in first line and having a
           progression free survival â‰¥ 3 months

        -  30 patients PD-L1 > 50% treated with pembrolizumab in first line and having a
           progression free survival < 3 months

        -  30 patients PD-L1 < 50% treated with cisplatin-based chemotherapy in first line
    
  